Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02470910 · ClinicalTrials.gov registry record · NA

Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

A NA study of Prostate Cancer and Adenocarcinoma of the Prostate Stage I, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT02470910 is a NA study of Prostate Cancer and Adenocarcinoma of the Prostate Stage I that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 15 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02470910, a NA study of Prostate Cancer and Adenocarcinoma of the Prostate Stage I, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This research study is evaluating whether a standard prostate MRI examination can improve radiation therapy planning for prostate cancer.

Interventions

  • DEVICE Magnetic Resonance Imaging

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2015-07
Est. Completion 2018-07
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT02470910

The ClinicalTrials.gov registry entry for NCT02470910 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Magnetic Resonance Imaging is the first listed.

NCT02470910 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02470910 about?

NCT02470910 is a clinical study titled "Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning". This research study is evaluating whether a standard prostate MRI examination can improve radiation therapy planning for prostate cancer.

What is the current status of trial NCT02470910?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2015-07. Estimated completion is 2018-07.

What conditions does trial NCT02470910 study?

This clinical trial studies the following conditions: Prostate Cancer, Adenocarcinoma of the Prostate Stage I, Adenocarcinoma of the Prostate Stage II, Adenocarcinoma of the Prostate Stage III.

What interventions are being tested in trial NCT02470910?

The interventions under investigation include: Magnetic Resonance Imaging (DEVICE).

Who is sponsoring clinical trial NCT02470910?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02470910 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.